Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrazinecarboxamide SCHEMBL22471913 | 0.81 | LMNA (0.38) | KDM4ENPC1RAB9A | |
| SCHEMBL25419135 | 0.80 | KDM4E (0.37) | KDM4ENPC1RAB9ANOTUM | |
| SCHEMBL2616386 | 0.80 | ELANE (0.31) | — | |
| SCHEMBL4080491 | 0.73 | KDM4E (0.33) | KDM4ENPC1RAB9A | |
| SCHEMBL9712934 | 0.72 | KDM4E (0.33) | KDM4ENPC1RAB9A | |
| SCHEMBL272220 | 0.69 | — | — | |
| SCHEMBL13855693 | 0.69 | NOTUM (0.38) | NOTUM | |
| SCHEMBL10202700 | 0.68 | EPHX2 (0.38) | — | |
| SCHEMBL21339904 | 0.68 | CYP1A2 (0.30) | — | |
| SCHEMBL17739747 | 0.68 | CYP1A2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091413-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2024-09-17 | — | — | US | disclosed |
| US-12036292-B2 | Heterobiaryl compounds and imaging agents for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-4146348-B1 | INHIBITORS OF NEK7 KINASE | HALIA THERAPEUTICS INC (US) | 2024-07-03 | — | — | EP | disclosed |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230416259-A1 | INHIBITORS OF NEK7 KINASE | HALIA THERAPEUTICS INC (US) | 2023-12-28 | — | — | US | disclosed |
| US-20230277523-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-20090197883-A1 | Diphenyl Substituted Cycloalkanes, Compositions Containing Such Compounds and Methods Of Use | MERCK SHARP & DOHME CORP. | 2009-08-06 | — | — | US | disclosed |
| WO-2007047496-A2 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-5086184-A | Herbicides | DOWELANCO (US) | 1992-02-04 | — | — | US | disclosed |
| EP-0378791-A2 | 3,4-Dimethyl-pyrrolidine derivatives | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1990-07-25 | — | — | EP | disclosed |
| US-4943634-A | HERBICIDES | ELI LILLY AND COMPANY (US) | 1990-07-24 | — | — | US | disclosed |
| US-4801718-A | HERBICIDES | ELI LILLY AND COMPANY (US) | 1989-01-31 | — | — | US | disclosed |
| US-4636243-A | HERBICIDES ISOXAZOLES | ELI LILLY AND COMPANY (US) | 1987-01-13 | — | — | US | disclosed |
| US-4515625-A | HERBICIDES | ELI LILLY AND COMPANY (US) | 1985-05-07 | — | — | US | disclosed |
| US-4416683-A | HERBICIDES | ELI LILLY AND COMPANY (US) | 1983-11-22 | — | — | US | disclosed |
| EP-0049071-A1 | N-arylbenzamide derivatives | ELI LILLY AND COMPANY (US) | 1982-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | KDM4E 1783/4885NPC1 377/4885RAB9A 3215/4885 |
| US-11713321-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | KDM4E 1778/4885NPC1 414/4885RAB9A 2987/4885 |
| US-12091413-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | KDM4E 1778/4885NPC1 414/4885RAB9A 2987/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | KDM4E 4052/4885NPC1 348/4885RAB9A 3477/4885 |
| US-20230277523-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | KDM4E 2140/4885NPC1 220/4885RAB9A 1798/4885 |
| US-12036292-B2 | Heterobiaryl compounds and imaging agents for imaging huntingtin protein | HTT, HYPK, ATXN2L | KDM4E 4813/4885NPC1 536/4885RAB9A 535/4885 |
| US-20230416259-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | KDM4E 1778/4885NPC1 414/4885RAB9A 2987/4885 |
| US-20090197883-A1 | Diphenyl Substituted Cycloalkanes, Compositions Containing Such Compounds and Methods Of Use | ALOX5, LTC4S, ALOX15B | KDM4E 3254/4885NPC1 450/4885RAB9A 4474/4885 |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | SLC10A1, SLC10A2, FABP3 | KDM4E 4631/4885NPC1 352/4885RAB9A 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.